LONDON, April 24 (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk (NOVOb.CO), opens new tab has raised its annual sales guidance several times a year.

STORY: Since launching its popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several times a year. But recent weak U.S. prescription data is leading some ...

LONDON (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several times a year. But recent weak U.S. prescription ...

Americans spent an estimated $71.7 billion on GLP-1 drugs including Ozempic and Wegovy in 2023, a 500 percent increase from their spending on such drugs five years earlier, according to a research ...

LONDON (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several times a year. But recent weak U.S. prescription data is ...

The United States Food and Drug Administration (FDA) has stopped the sale of copycat versions of Ozempic and Wegovy, the Type 2 diabetes drugs used for weight loss. In 2022, the FDA announced ...

People who’ve been using more affordable copycat versions of Ozempic or Wegovy to lose weight will no longer have that option. Compounding pharmacies have been allowed to make generic ...

A daily pill appears to lower blood sugar in people with type 2 diabetes as effectively as injectable drugs like Ozempic and Mounjaro. The medication, called orforglipron, also led to substantial ...